000513 丽珠集团
已收盘 05-06 15:00:00
资讯
新帖
简况
丽珠集团(000513.SZ)已累计回购股份1.24%股份 耗资约4.07亿元
智通财经 · 05-06 11:13
丽珠集团(000513.SZ)已累计回购股份1.24%股份 耗资约4.07亿元
丽珠集团:4月29日接受机构调研,国信证券参与
证券之星 · 04-30
丽珠集团:4月29日接受机构调研,国信证券参与
丽珠集团(000513.SZ)发布一季度业绩,归母净利润6.37亿元,同比增长4.75%
智通财经 · 04-23
丽珠集团(000513.SZ)发布一季度业绩,归母净利润6.37亿元,同比增长4.75%
【丽珠集团:副总裁杨代宏因工作调整原因辞职】丽珠集团4月23日公告,公司董事会收到副总裁杨代宏的书面辞职报告,杨代宏因工作调整原因申请辞去公司副总裁职务,辞任后仍在公司担任其他职务,辞职申请自送达公司董事会之日起生效。
金融界 · 04-23
【丽珠集团:副总裁杨代宏因工作调整原因辞职】丽珠集团4月23日公告,公司董事会收到副总裁杨代宏的书面辞职报告,杨代宏因工作调整原因申请辞去公司副总裁职务,辞任后仍在公司担任其他职务,辞职申请自送达公司董事会之日起生效。
丽珠集团:公司始终积极响应国家战略布局,密切关注粤港澳大湾区发展机遇
证券之星 · 04-21
丽珠集团:公司始终积极响应国家战略布局,密切关注粤港澳大湾区发展机遇
丽珠集团:4月17日接受机构调研,工银瑞信、华泰证券等多家机构参与
证券之星 · 04-17
丽珠集团:4月17日接受机构调研,工银瑞信、华泰证券等多家机构参与
健康元:关于子公司管理,健康元与丽珠集团长期保持专业化独立运营
证券之星 · 04-17
健康元:关于子公司管理,健康元与丽珠集团长期保持专业化独立运营
丽珠集团:4月15日召开业绩说明会,投资者参与
证券之星 · 04-16
丽珠集团:4月15日召开业绩说明会,投资者参与
丽珠集团:自主技术能力已能支撑重点项目推进需求
金融界 · 03-11
丽珠集团:自主技术能力已能支撑重点项目推进需求
健康元:公司在AI制药领域已有布局,目前关于DeepSeek - R1 671B “满血” 版的部署正在进行中,而公司控股子公司丽珠集团已在近期完成了本地化部署
互动易 · 03-10
健康元:公司在AI制药领域已有布局,目前关于DeepSeek - R1 671B “满血” 版的部署正在进行中,而公司控股子公司丽珠集团已在近期完成了本地化部署
丽珠集团新提交“丽珠”商标注册申请
证券之星 · 03-08
丽珠集团新提交“丽珠”商标注册申请
丽珠集团:公司近年暂缓了部分生物药的研发进展
美港电讯 · 03-04
丽珠集团:公司近年暂缓了部分生物药的研发进展
加载更多
公司概况
公司名称:
丽珠医药集团股份有限公司
所属行业:
医药制造业
上市日期:
1993-10-28
主营业务:
丽珠医药集团股份有限公司的主营业务是医药产品的研发、生产及销售。公司的主要产品是注射用醋酸亮丙瑞林微球(贝依)、注射用尿促卵泡素(丽申宝)、注射用尿促性素(乐宝得)、艾普拉唑肠溶片及注射用艾普拉唑钠(壹丽安)、枸橼酸铋钾系列产品(丽珠得乐)、维三联(枸橼酸铋钾片/替硝唑片/克拉霉素片)、马来酸氟伏沙明片(瑞必乐)、盐酸哌罗匹隆片(康尔汀)、参芪扶正注射液、抗病毒颗粒。
发行价格:
6.38
{"stockData":{"symbol":"000513","market":"SZ","secType":"STK","nameCN":"丽珠集团","latestPrice":34.69,"timestamp":1746515028000,"preClose":34.58,"halted":0,"volume":6000583,"delay":0,"changeRate":0.0032,"floatShares":584000000,"shares":911000000,"eps":2.2933,"marketStatus":"已收盘","change":0.11,"latestTime":"05-06 15:00:00","open":34.65,"high":34.73,"low":34.31,"amount":207000000,"amplitude":0.0121,"askPrice":34.7,"askSize":112,"bidPrice":34.69,"bidSize":509,"shortable":0,"etf":0,"ttmEps":2.2933,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746581400000},"marketStatusCode":5,"adr":0,"adjPreClose":34.58,"symbolType":"stock","openAndCloseTimeList":[[1746495000000,1746502200000],[1746507600000,1746514800000]],"highLimit":38.04,"lowLimit":31.12,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":911345730,"isCdr":false,"pbRate":2.22,"roa":"--","peRate":15.126673,"roe":"4.55%","epsLYR":2.24,"committee":0.152898,"marketValue":31615000000,"turnoverRate":0.0103,"status":0,"hkstockBrief":{"symbol":"01513","market":"HK","secType":"STK","nameCN":"丽珠医药","latestPrice":26.3,"timestamp":1746518913014,"preClose":25.9,"halted":0,"volume":749674,"delay":0,"premium":"-29.58"},"floatMarketCap":20271000000},"requestUrl":"/m/hq/s/000513","defaultTab":"news","newsList":[{"id":"2533968946","title":"丽珠集团(000513.SZ)已累计回购股份1.24%股份 耗资约4.07亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533968946","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533968946?lang=zh_cn&edition=full","pubTime":"2025-05-06 19:13","pubTimestamp":1746530008,"startTime":"0","endTime":"0","summary":"智通财经APP讯,丽珠集团(000513.SZ)发布公告,截至2025年4月30日,公司通过集中竞价交易方式回购了公司A股股份共计1131.89万股,占公司总股本的比例为1.24%,购买的最高价为人民币38.37元/股,最低价为人民币33.21元/股,已使用的资金总额为人民币4.07亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1289749.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"丽珠集团(000513.SZ)已累计回购股份1.24%股份 耗资约4.07亿元","news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000513","BK0187","BK0239","BK0028","BK0188"],"gpt_icon":0},{"id":"2531747281","title":"丽珠集团:4月29日接受机构调研,国信证券参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2531747281","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531747281?lang=zh_cn&edition=full","pubTime":"2025-04-30 09:58","pubTimestamp":1745978288,"startTime":"0","endTime":"0","summary":"证券之星消息,2025年4月29日丽珠集团发布公告称公司于2025年4月29日接受机构调研,国信证券首席分析师 陈曦炳 分析师 肖婧舒参与。抗病毒颗粒在 2023 年高基数后逐步归常态化增长,如果不考虑流感等突发因素,预计今年有小幅增长。参芪扶正注射液受益于医保后缀解限带来的市场扩容,销售有望持续攀升。2024年度,公司现金分红及股份购总金额占本年度公司归属于股东净利润的比例约为 88%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025043000014814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0183","002736","BK0187","000513","BK0239","BK0028","BK0276"],"gpt_icon":0},{"id":"2529825578","title":"丽珠集团(000513.SZ)发布一季度业绩,归母净利润6.37亿元,同比增长4.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529825578","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529825578?lang=zh_cn&edition=full","pubTime":"2025-04-23 17:21","pubTimestamp":1745400116,"startTime":"0","endTime":"0","summary":"智通财经APP讯,丽珠集团(000513.SZ)发布2025年一季度报告,第一季度,公司实现营业收入31.81亿元,同比下降1.92%。归属于上市公司股东的净利润6.37亿元,同比增长4.75%。归属于上市公司股东的扣除非经常性损益的净利润6.19亿元,同比增长4.82%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1283138.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000513"],"gpt_icon":0},{"id":"2529228285","title":"【丽珠集团:副总裁杨代宏因工作调整原因辞职】丽珠集团4月23日公告,公司董事会收到副总裁杨代宏的书面辞职报告,杨代宏因工作调整原因申请辞去公司副总裁职务,辞任后仍在公司担任其他职务,辞职申请自送达公司董事会之日起生效。","url":"https://stock-news.laohu8.com/highlight/detail?id=2529228285","media":"金融界","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529228285?lang=zh_cn&edition=full","pubTime":"2025-04-23 16:57","pubTimestamp":1745398645,"startTime":"0","endTime":"0","summary":"丽珠集团4月23日公告,公司董事会收到副总裁杨代宏的书面辞职报告,杨代宏因工作调整原因申请辞去公司副总裁职务,辞任后仍在公司担任其他职务,辞职申请自送达公司董事会之日起生效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/23165749789708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0188","BK0028","BK0239","BK0187","000513"],"gpt_icon":0},{"id":"2529815676","title":"丽珠集团:公司始终积极响应国家战略布局,密切关注粤港澳大湾区发展机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2529815676","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529815676?lang=zh_cn&edition=full","pubTime":"2025-04-21 09:06","pubTimestamp":1745197565,"startTime":"0","endTime":"0","summary":"证券之星消息,丽珠集团(000513)04月21日在投资者关系平台上答复投资者关心的问题。投资者提问:公司身处珠海,请问“澳门横琴”新定位下的澳琴大健康产业合作对公司是利好吗?公司有采取什么举措去抓住这个政策红利吗?谢谢!丽珠集团回复:尊敬的投资者,您好!公司始终积极响应国家战略布局,密切关注粤港澳大湾区发展机遇。我们将持续深化与区域产业资源的协同合作,充分发挥自身在医药健康领域的专业优势,通过加强技术交流、优化资源配置等方式,主动把握政策导向下的发展契机。谢谢您的关注。以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042100002031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1567","BK0028","BK1507","BK0188","00737","BK0239","BK1185","BK0187","000513"],"gpt_icon":0},{"id":"2528716008","title":"丽珠集团:4月17日接受机构调研,工银瑞信、华泰证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2528716008","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528716008?lang=zh_cn&edition=full","pubTime":"2025-04-17 20:05","pubTimestamp":1744891523,"startTime":"0","endTime":"0","summary":"证券之星消息,2025年4月17日丽珠集团发布公告称公司于2025年4月17日接受机构调研,工银瑞信基金经理 丁洋、华泰证券分析师 沈卢庆 分析师 孙茗馨、前海开源研究员 于成龙、富国基金研究员 刘锡源、建信基金研究员 郑丁源、永赢基金研究员 张晓榕参与。2025年该品种不受医保降价影响,以量换价预计今年能有所贡献。重组人促卵泡激素注射液已于 2025年初申报上市;重组抗人 IL-17A/F人","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025041700032450.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU1979443071.USD","06886","000513","BK0276","LU1781817850.SGD","LU1064131003.USD","LU1580142542.USD","BK1147","601688","BK1564","BK0188","BK0183","BK0012","LU2148510915.USD","LU1328615791.USD","BK0028","LU1934453819.USD","BK0239","BK0187"],"gpt_icon":0},{"id":"2528793721","title":"健康元:关于子公司管理,健康元与丽珠集团长期保持专业化独立运营","url":"https://stock-news.laohu8.com/highlight/detail?id=2528793721","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528793721?lang=zh_cn&edition=full","pubTime":"2025-04-17 17:39","pubTimestamp":1744882747,"startTime":"0","endTime":"0","summary":"证券之星消息,健康元04月17日在投资者关系平台上答复投资者关心的问题。二级市场流动性受多重因素影响,公司始终重视市值管理,将通过稳健业绩,重视股东回报,加强创新药管线落地等,逐步增进市场认可。未来若涉及并购重组等重大事项,公司将严格履行信披义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025041700026991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600380","BK0239","BK0114","BK0077","BK0028","BK0046","BK0188","BK0187","000513"],"gpt_icon":0},{"id":"2527257234","title":"丽珠集团:4月15日召开业绩说明会,投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2527257234","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527257234?lang=zh_cn&edition=full","pubTime":"2025-04-16 14:10","pubTimestamp":1744783827,"startTime":"0","endTime":"0","summary":"证券之星消息,2025年4月16日丽珠集团发布公告称公司于2025年4月15日召开业绩说明会。丽珠的诊断试剂板块已逐步形成了细分市场的壁垒优势。亮丙瑞林微球一个月和三个月的产品定位和目标患者群体略有不同。同时,公司也布局了三个月缓释的亮丙瑞林微球产品,目前正在进行 BE试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025041600017187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000513","BK0239","BK0187","BK0028"],"gpt_icon":0},{"id":"2518754633","title":"丽珠集团:自主技术能力已能支撑重点项目推进需求","url":"https://stock-news.laohu8.com/highlight/detail?id=2518754633","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518754633?lang=zh_cn&edition=full","pubTime":"2025-03-11 12:33","pubTimestamp":1741667630,"startTime":"0","endTime":"0","summary":"金融界3月11日消息,有投资者在互动平台向丽珠集团提问:2016年参股ABCYTE40%的子公司现在状况是?公司回答表示:公司于2016年对ABCYTE的参股投资,是当时基于特定阶段研发技术协同需求的阶段性布局,以推动早期技术探索和资源整合。公司始终以提升自主创新能力为核心,对于历史参股企业的合作定位,根据不同阶段的研发需求进行动态优化。目前,随着公司自主研发体系的持续完善,现阶段自主技术能力已能够支撑重点项目的推进需求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/11123348651503.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["000513","BK0187","BK0188","BK0028","BK0239"],"gpt_icon":0},{"id":"2518215899","title":"健康元:公司在AI制药领域已有布局,目前关于DeepSeek - R1 671B “满血” 版的部署正在进行中,而公司控股子公司丽珠集团已在近期完成了本地化部署","url":"https://stock-news.laohu8.com/highlight/detail?id=2518215899","media":"互动易","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518215899?lang=zh_cn&edition=full","pubTime":"2025-03-10 16:18","pubTimestamp":1741594681,"startTime":"0","endTime":"0","summary":"有投资者向健康元提问, 近期了解到丽珠正式完成了 DeepSeek 的部署应用,请问健康元是否也进行了AI本地化部署的相关工作?公司回答表示,您好,公司在AI制药领域已有布局,目前关于DeepSeek - R1 671B “满血” 版的部署正在进行中,而公司控股子公司丽珠集团已在近期完成了本地化部署。后续,公司将密切关注AI领域的快速发展和研究,积极推动AI在各业务模块的全面应用,以期进一步优化业务流程,提升工作效率。感谢您对公司的关注!","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310163551abf287c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310163551abf287c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600380","000513"],"gpt_icon":0},{"id":"2518897424","title":"丽珠集团新提交“丽珠”商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2518897424","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518897424?lang=zh_cn&edition=full","pubTime":"2025-03-09 05:19","pubTimestamp":1741468782,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示,近日丽珠医药集团股份有限公司新提交“丽珠”商标注册申请。商标申请详情如下:今年以来丽珠医药集团股份有限公司新申请注册商标2件,截止目前公司共持有注册商标1152件,另有58件商标尚在注册申请中。数据来源:企查查以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030900000132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000513","BK0187","BK0188","BK0028","BK0239"],"gpt_icon":0},{"id":"2516415627","title":"丽珠集团:公司近年暂缓了部分生物药的研发进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2516415627","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516415627?lang=zh_cn&edition=full","pubTime":"2025-03-04 19:45","pubTimestamp":1741088709,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["000513","159839","BK0239","BK0028","159646","BK0188","BK0187"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1746577313409,"stockEarnings":[{"period":"1week","weight":0.002},{"period":"1month","weight":-0.0414},{"period":"3month","weight":-0.0501},{"period":"6month","weight":-0.0983},{"period":"1year","weight":-0.1116},{"period":"ytd","weight":-0.0871}],"compareEarnings":[{"period":"1week","weight":0.009},{"period":"1month","weight":-0.0077},{"period":"3month","weight":0.0268},{"period":"6month","weight":-0.0445},{"period":"1year","weight":0.0558},{"period":"ytd","weight":-0.0106}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"丽珠医药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"52348人(较上一季度减少0.90%)","perCapita":"11162股","listingDate":"1993-10-28","address":"广东省珠海市金湾区创业北路38号总部大楼","registeredCapital":"91134万元","survey":" 丽珠医药集团股份有限公司的主营业务是医药产品的研发、生产及销售。公司的主要产品是注射用醋酸亮丙瑞林微球(贝依)、注射用尿促卵泡素(丽申宝)、注射用尿促性素(乐宝得)、艾普拉唑肠溶片及注射用艾普拉唑钠(壹丽安)、枸橼酸铋钾系列产品(丽珠得乐)、维三联(枸橼酸铋钾片/替硝唑片/克拉霉素片)、马来酸氟伏沙明片(瑞必乐)、盐酸哌罗匹隆片(康尔汀)、参芪扶正注射液、抗病毒颗粒。","listedPrice":6.38},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"丽珠集团(000513)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供丽珠集团(000513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"丽珠集团,000513,丽珠集团股票,丽珠集团股票老虎,丽珠集团股票老虎国际,丽珠集团行情,丽珠集团股票行情,丽珠集团股价,丽珠集团股市,丽珠集团股票价格,丽珠集团股票交易,丽珠集团股票购买,丽珠集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"丽珠集团(000513)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供丽珠集团(000513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}